NL301304I2 - aprocitentan of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

aprocitentan of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301304I2
Authority: NL; Netherlands
Prior art keywords: aprocitentan; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2007-08-17

Application number

NL301304C

Other languages

English (en)

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2024-12-10

Publication date

2024-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301304(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-12-10 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2024-12-19 Publication of NL301304I2 publication Critical patent/NL301304I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)

NL301304C 2007-08-17 2024-12-10 aprocitentan of een farmaceutisch aanvaardbaar zout daarvan NL301304I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IB2007053292		2007-08-17
IB2008052571		2008-06-26
PCT/IB2008/053282 WO2009024906A1 (en)	2007-08-17	2008-08-15	4-pyrimidinesulfamide derivative

Publications (1)

Publication Number	Publication Date
NL301304I2 true NL301304I2 (nl)	2024-12-19

Family

ID=40140023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301304C NL301304I2 (nl)	2007-08-17	2024-12-10	aprocitentan of een farmaceutisch aanvaardbaar zout daarvan

Country Status (31)

Country	Link
US (1)	US8324232B2 (nl)
EP (1)	EP2190837B1 (nl)
JP (1)	JP5323075B2 (nl)
KR (1)	KR101528946B1 (nl)
CN (1)	CN101772494B (nl)
AR (1)	AR070018A1 (nl)
AU (1)	AU2008290234B2 (nl)
BR (1)	BRPI0815360B8 (nl)
CA (1)	CA2695511C (nl)
CY (1)	CY1113255T1 (nl)
DK (1)	DK2190837T3 (nl)
ES (1)	ES2394584T3 (nl)
FI (1)	FIC20240041I1 (nl)
FR (1)	FR24C1047I1 (nl)
HK (1)	HK1144196A1 (nl)
HR (1)	HRP20120878T1 (nl)
HU (1)	HUS2400041I1 (nl)
IL (1)	IL203936A (nl)
MA (1)	MA31702B1 (nl)
MX (1)	MX2010001837A (nl)
MY (1)	MY152281A (nl)
NL (1)	NL301304I2 (nl)
NO (1)	NO2024053I1 (nl)
NZ (1)	NZ583990A (nl)
PL (1)	PL2190837T3 (nl)
PT (1)	PT2190837E (nl)
RU (1)	RU2485116C2 (nl)
SI (1)	SI2190837T1 (nl)
TW (1)	TWI411437B (nl)
WO (1)	WO2009024906A1 (nl)
ZA (1)	ZA201001872B (nl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2907811A1 (en) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives
WO2017093903A1 (en) *	2015-11-30	2017-06-08	Laurus Labs Private Limited	An improved process for the preparation of macitentan
WO2017191565A1 (en) *	2016-05-04	2017-11-09	Shilpa Medicare Limited	Process for preparation of macitentan
EP3658140A1 (en) *	2017-02-27	2020-06-03	Idorsia Pharmaceuticals Ltd	Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
US12144811B2 (en) *	2017-11-30	2024-11-19	Idorsia Pharmaceuticals Ltd	Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
CN108997223B (zh) *	2018-08-09	2020-06-30	浙江先锋科技股份有限公司	5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
TWI841649B (zh)	2018-12-21	2024-05-11	瑞士商艾克泰聯製藥有限公司	用於治療肺動脈高血壓之醫藥組成物
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
EP4056182A1 (en) *	2019-11-07	2022-09-14	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of aprocitentan, preparation method therefor and use thereof
US20230167090A1 (en)	2020-05-21	2023-06-01	Teva Pharmaceuticals International Gmbh	Solid state forms of aprocitentan and process for preparation thereof
WO2023111797A1 (en) *	2021-12-17	2023-06-22	Janssen Biotech, Inc.	Pyrimidine sulfamide derivatives and process for manufacturing them
CN119255805A (zh)	2022-05-22	2025-01-03	爱杜西亚药品有限公司	用于治疗高血压的阿普昔腾坦
KR20250019676A (ko)	2022-05-25	2025-02-10	이도르시아 파마슈티컬스 리미티드	소듐 (5-(4-브로모페닐)-6-(2-((5-브로모피리미딘-2-일)옥시)에톡시)피리미딘-4-일)(술파모일)아미드의 결정질 형태

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2801584A1 (de)	1978-01-14	1979-07-19	Bayer Ag	Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja)	1990-08-22	1992-04-06	Sanwa Kagaku Kenkyusho Co Ltd	難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en)	1993-06-28	2000-06-21	Hoffmann La Roche	Novel Sulfonylamino Pyrimidines
US5523204A (en)	1993-12-10	1996-06-04	Becton Dickinson And Company	Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de)	1994-11-25	1996-06-06	F. Hoffmann-La Roche Ag	Sulfonamide und deren verwendung als heilmittel
TW313568B (nl)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
TW442301B (en)	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
WO1997022595A1 (fr)	1995-12-20	1997-06-26	Yamanouchi Pharmaceutical Co., Ltd.	Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
TWI284642B (en)	1999-01-18	2007-08-01	Hoffmann La Roche	Novel heterocyclic sulfonamides
HUP0201402A3 (en)	1999-09-03	2003-12-29	Actelion Pharmaceuticals Ltd	Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
AU3536701A (en)	1999-12-22	2001-07-03	Actelion Pharmaceuticals Ltd	Butyne diol derivatives
US20040062803A1 (en)	1999-12-22	2004-04-01	Hedden David B.	Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1244657B1 (en)	1999-12-31	2004-12-29	Encysive Pharmaceuticals Inc.	Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2001081335A1 (en)	2000-04-20	2001-11-01	Actelion Pharmaceuticals Ltd	Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en)	2000-04-25	2001-11-07	Actelion Pharmaceuticals Ltd	Substituted sulfonylaminopyrimidines
JP2001335469A (ja)	2000-05-26	2001-12-04	Lion Corp	固体製剤の製造方法
MXPA02012795A (es)	2000-06-28	2004-07-30	Teva Pharma	Carvedilol.
WO2002046172A2 (en)	2000-12-07	2002-06-13	Cv Therapeutics, Inc.	Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
WO2002053557A1 (en)	2000-12-18	2002-07-11	Actelion Pharmaceuticals Ltd	Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr)	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
KR20030041577A (ko)	2001-11-20	2003-05-27	디디에스텍주식회사	난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
EP1480679B1 (en)	2002-02-26	2007-05-23	Astrazeneca AB	Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US7452896B2 (en) *	2002-12-02	2008-11-18	Actelion Pharmaceuticals Ltd.	Pyrimidine-sulfamides and their use as endothelian receptor antagonist
AU2004216258B2 (en)	2003-02-25	2006-10-19	Eli Lilly And Company	Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
MY151003A (en) *	2005-09-12	2014-03-31	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
AU2009215329B2 (en)	2008-02-20	2014-08-21	Actelion Pharmaceuticals Ltd	Combination comprising paclitaxel for treating ovarian cancer
PT2315587T (pt)	2008-08-13	2018-01-31	Actelion Pharmaceuticals Ltd	Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

2008
- 2008-02-07 MX MX2010001837A patent/MX2010001837A/es active IP Right Grant
- 2008-08-14 AR ARP080103552A patent/AR070018A1/es not_active Application Discontinuation
- 2008-08-15 PL PL08807330T patent/PL2190837T3/pl unknown
- 2008-08-15 US US12/673,413 patent/US8324232B2/en active Active
- 2008-08-15 MY MYPI20100680 patent/MY152281A/en unknown
- 2008-08-15 CN CN2008801016796A patent/CN101772494B/zh active Active
- 2008-08-15 PT PT08807330T patent/PT2190837E/pt unknown
- 2008-08-15 WO PCT/IB2008/053282 patent/WO2009024906A1/en active Application Filing
- 2008-08-15 NZ NZ583990A patent/NZ583990A/en unknown
- 2008-08-15 DK DK08807330.9T patent/DK2190837T3/da active
- 2008-08-15 KR KR1020107004945A patent/KR101528946B1/ko active IP Right Grant
- 2008-08-15 BR BRPI0815360A patent/BRPI0815360B8/pt active IP Right Grant
- 2008-08-15 ES ES08807330T patent/ES2394584T3/es active Active
- 2008-08-15 AU AU2008290234A patent/AU2008290234B2/en active Active
- 2008-08-15 TW TW097131323A patent/TWI411437B/zh active
- 2008-08-15 CA CA2695511A patent/CA2695511C/en active Active
- 2008-08-15 RU RU2010109543/04A patent/RU2485116C2/ru active
- 2008-08-15 JP JP2010520674A patent/JP5323075B2/ja active Active
- 2008-08-15 EP EP08807330A patent/EP2190837B1/en active Active
- 2008-08-15 SI SI200830785T patent/SI2190837T1/sl unknown
2010
- 2010-02-14 IL IL203936A patent/IL203936A/en active IP Right Grant
- 2010-03-12 MA MA32692A patent/MA31702B1/fr unknown
- 2010-03-16 ZA ZA2010/01872A patent/ZA201001872B/en unknown
- 2010-11-12 HK HK10110542.0A patent/HK1144196A1/xx unknown
2012
- 2012-10-25 CY CY20121101015T patent/CY1113255T1/el unknown
- 2012-10-30 HR HRP20120878AT patent/HRP20120878T1/hr unknown
2024
- 2024-11-27 HU HUS2400041C patent/HUS2400041I1/hu unknown
- 2024-12-02 FI FIC20240041C patent/FIC20240041I1/fi unknown
- 2024-12-03 NO NO2024053C patent/NO2024053I1/no unknown
- 2024-12-05 FR FR24C1047C patent/FR24C1047I1/fr active Active
- 2024-12-10 NL NL301304C patent/NL301304I2/nl unknown

Also Published As

Publication number	Publication date
BRPI0815360A8 (pt)	2017-12-26
KR20100052517A (ko)	2010-05-19
JP2010536742A (ja)	2010-12-02
NZ583990A (en)	2012-06-29
AU2008290234A1 (en)	2009-02-26
CA2695511C (en)	2015-11-03
DK2190837T3 (da)	2012-10-08
HK1144196A1 (en)	2011-02-02
FIC20240041I1 (fi)	2024-12-02
NO2024053I1 (no)	2024-12-03
CN101772494A (zh)	2010-07-07
PT2190837E (pt)	2012-10-31
BRPI0815360B1 (pt)	2018-12-04
CA2695511A1 (en)	2009-02-26
TW200927122A (en)	2009-07-01
TWI411437B (zh)	2013-10-11
KR101528946B1 (ko)	2015-06-15
AU2008290234B2 (en)	2013-11-21
WO2009024906A1 (en)	2009-02-26
IL203936A (en)	2016-03-31
ZA201001872B (en)	2011-05-25
MA31702B1 (fr)	2010-09-01
HUS2400041I1 (hu)	2024-12-28
RU2485116C2 (ru)	2013-06-20
MX2010001837A (es)	2010-03-10
ES2394584T3 (es)	2013-02-04
JP5323075B2 (ja)	2013-10-23
CY1113255T1 (el)	2016-04-13
RU2010109543A (ru)	2011-09-27
HRP20120878T1 (hr)	2012-11-30
BRPI0815360B8 (pt)	2021-05-25
EP2190837B1 (en)	2012-08-15
BRPI0815360A2 (pt)	2015-02-10
PL2190837T3 (pl)	2013-01-31
AR070018A1 (es)	2010-03-10
SI2190837T1 (sl)	2012-11-30
FR24C1047I1 (fr)	2025-01-10
EP2190837A1 (en)	2010-06-02
US8324232B2 (en)	2012-12-04
CN101772494B (zh)	2013-05-15
MY152281A (en)	2014-09-15
US20120142716A1 (en)	2012-06-07

Publication	Publication Date	Title
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I1 (nl)	2020-03-25	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301106I2 (nl)	2021-08-03	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301304I2 (nl)	2024-12-19	aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301284I2 (nl)	2024-09-04	Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301299I2 (nl)	2024-12-11	Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL301096I2 (nl)	2021-04-12	Filgotinib of een zout daarvan
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NL301028I2 (nl)	2020-04-15	Gilteritinib of een zout ervan
NL301202I1 (nl)	2022-11-09	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NO2017059I2 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav